Amneal Pharmaceuticals Profit Margin

Amneal Pharmaceuticals (AMRX) currently reports a profit margin of 2.58% as of March 2026. That compares with 0.34% in the prior-year period — up 655.3% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Amneal Pharmaceuticals's profit margin history and peer comparisons.

Amneal Pharmaceuticals's profit margin increased from 0.34% to 2.58% — a 655.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amneal Pharmaceuticals's profit margin of 2.58% is lower than the Healthcare sector average of 15.58%. That is roughly 83.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Amneal Pharmaceuticals's current 2.58% should be judged against Healthcare norms (sector average: 15.58%) and against AMRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 2.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Amneal Pharmaceuticals, and consider following AMRX for alerts when major investors trade the stock.